Insulin deficiency in type 1 diabetes (T1D) is generally considered a consequence of specific beta-cell loss. Since healthy pancreatic islets consist of ~65% beta cells, this would lead to reduced islet size if the beta cells are not replaced by other cells or tissue.
Introduction
The number of islets in the human pancreas is about 1-2 million with an absolute majority of islets with a diameter below 50 µm. However, the islets with largest contribution to the total endocrine volume have a diameter of about 120-150 µm. A tremendous expansion of the total islet volume occurs during childhood (1) . If this expansion of the islet mass mainly occurs from a so far not identified pancreatic endocrine stem cell or via cell replication remains unknown (2; 3).
The loss of beta cells in type 1 diabetes (T1D) occurs over a period of several years, or even decades, both before and after clinical diagnosis. Insulin deficiency could tentatively be caused by 1) a specific loss of beta cells, the currently dominating view, or 2) by an inability to establish a beta-cell mass large enough to meet increased physiological demands. The relative importance of the two alternatives can be tested by morphometry of pancreases of subjects with or without T1D. We postulate that, if T1D is mainly caused by specific destruction of the beta cells, islets size would be reduced, since this cell-type constitutes about 65% of all cells within an islet (4) , but the total number of islets would be preserved. Also, islets with signs of preceding beta-cell destruction, i.e. fibrosis, would be frequently found. Alternatively, if the main cause of insulin deficiency is an inability to establish islet mass during childhood and adolescence, a reduced number of islets would be found. In this study, we therefore compared the total islet number/mm 2 pancreatic parenchyma (islet density) and the islet-size distribution in pancreatic biopsies obtained from patients with recent-onset T1D included in the Diabetes Virus Detection-study (DiViD) (5) and organ donors with T1D since several years, with that in matched non-diabetic organ donors (Table 1) .
Research design and methods

Biopsies
Pancreatic biopsies were obtained from six patients with recent-onset T1D, included in the DiViD study.
Mean age was 28 years (range 24-35). Biopsies were taken laparoscopically from the pancreas tail 3-9 weeks after diagnosis. Two tissue samples from separate parts of each biopsy were analyzed, except in case 2 where three tissue samples were analyzed. Additional information regarding clinical history and surgery has been described previously (5) . The DiViD study was approved by the Norwegian Governments Regional Ethics Committee and all patients gave informed written consent after having obtained oral and written information. Pancreatic tail biopsies were also collected from seven brain-dead organ donors enrolled into the Nordic Network for Islet Transplantation, with a history of more than 200 weeks (3.8 years) of type 1 diabetes, and from nine non-diabetic organ donors. The non-diabetic organ donors were age-matched to the DiViD patients with recent onset T1D ( Visualization was done using EnVision G|2 Doublestain System, Rabbit/Mouse (Agilent, Cat: K536111-
2)
All slides were scanned with the Aperio ScanScope system (Aperio Technologies, Oxford, UK). In the sections stained for synaptophysin, the borders of each pancreatic islet were identified morphologically and marked using the pen tool in Aperio ImageScope. The total tissue area in each section was calculated using the pen tool and the negative pen tool. Morphological identification of islets using the pen tool was also applied on the sections stained for glucagon/CD3 and insulin/CD3. The glucagon-and insulincontaining areas were calculated in the sections from the DiViD patients and from the non-diabetic control donors, using the Positive Pixel Count Algorithm in Aperio ImageScope version 12.3 software (Aperio Technologies). All islets with an area >491 µm 2 (corresponding to a diameter of >25 µm), approximately corresponding to islets containing a minimum of five glucagon-or insulin-containing cells, were regarded for analysis. Circularity is a measure of the roundness of an object, it can be calculated when the area and perimeter is known through the formula: C = 4πA/P 2 , where C is the circularity, A is the area and P is the perimeter. A perfect circle has C = 1. In total, 12.7 cm 2 pancreatic tissue from patients with recent onset T1D, 6.81 cm 2 from donors with longstanding T1D, and 4.97 cm 2 from control organ donors was analyzed.
Multiplex staining and analysis
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Data analysis
Calculations and statistical analyses were carried out using R version 3.3.0. Differences between groups were analyzed using non-parametric ANOVA (Kruskal-Wallis) and the Mann-Whitney U-test.
Results
Morphological characterization of islets in non-diabetic subjects, subjects with recent onset or longstanding T1D
Islets with various morphological appearance were seen in patients with recent onset T1D. In 97% (92-100%) of the islets in non-diabetic subjects, ≥60% of the endocrine area stained positive for insulin. In subjects with recent onset T1D, 13% (3.0-40%) of the islets contained ≥60% insulin, 13% (5.1-22%) contained 20-60% insulin and 74%
(47-90%) contained ≤20% insulin (fig 1) . In subjects with longstanding T1D, no insulin-containing islets were found and the absolute majority of the islet cells expressed glucagon. However, in 5 of the 7 subjects with longstanding T1D, single insulin-positive cells were found scattered throughout the exocrine parenchyma, albeit to a lower extent than in controls.
Almost all islets were seemingly intact without discernable necrotic or large fibrotic areas regardless of disease status. Some islets having irregular borders were observed, especially among subjects with recent-onset T1D but most islets had a normal architecture. Circularity was used to measure this phenomenon and, although there was a tendency to lower circularity when comparing recent-onset T1D subjects with control subjects, no statistically significant differences were seen (fig 2a) .
Islet size distribution
The percentage of islets in each size category was calculated in relation to the total number of islets (fig 2c) . There was no difference in islet size distribution between the three groups of subjects. This was confirmed by fitting an exponential curve (y = a × e -bx ) to the mean number of islets per mm 2 per islet size category in each donor (fig 2d) .
No statistically significant differences were seen between any of the groups comparing the values for the slope coefficient b between the groups (b in the control group was 0.028, 0.030 in recent onset T1D and 0.034 in longstanding T1D). (fig 2b) . The differences in mean islet size between controls and either of the groups of subjects with T1D were not statistically significant. However, islets from subjects with recent onset T1D was significantly larger than from subjects with longstanding T1D (p<0.05).
Islet density in the pancreas
A total of 2054, 1075, and 2197 islets were counted in subjects with recent onset T1D, longstanding T1D, and non-diabetic controls, respectively. The median islet density was significantly lower in subjects with recent onset T1D (1.7 islets/mm 2 , range 1.3-1.8) or longstanding T1D (1.8 islets/mm 2 , range 0.6-2.4) compared to non-diabetic control subjects (4.4 islets/mm2, range 3.4-7.7) (p<0.005). No difference in islet density was found between subjects with recent onset T1D and subjects with longstanding T1D (fig 2e) .
The number of islets/mm 2 pancreas in each size category was calculated (fig 2f) .
In each size category the number of islets/mm 2 was reduced with about 50% in both categories of diabetic subjects when compared to non-diabetic subjects. This was confirmed in the exponential curve described above (fig 2d) , and then comparing the values for the constant a between the groups. The mean a-value in the control group was 9.0, significantly (p<0.0115) higher than in the two T1D groups (2.5 in recent onset and 2.8 in longstanding T1D). No statistically significant differences were seen between subjects with recent onset and longstanding T1D.
Altered expression of transcription factors in alpha-cells in recent-onset and longstanding type 1 diabetes
In islets from non-diabetic subjects, and in insulin-containing islets with apparent normal number of insulin-containing cells from the DIVID subjects, the beta-cell transcription factor PDX1 was localized in nuclei of insulin-containing cells, and the alpha-cell transcription factor ARX localized in nuclei of glucagon-containing cells, as expected. However, PDX1 expression was frequently found in nuclei of glucagoncontaining cells in islets with reduced number of insulin-containing cells in recent-onset subjects and in islets without insulin-containing cells in both recent-onset and longstanding T1D subjects (fig 3) . No insulin-containing cell expressing nuclear staining with ARX was found and no cells were found with discernable co-expression of glucagon and insulin.
Discussion
The results presented show preserved islet size distribution, but a marked reduction in islet density in subjects with recent onset T1D when compared with non-diabetic subjects and that no further reduction in islet numbers/mm 2 occurs with increased disease duration. Several previous publications have shown a marked reduction in beta cell volume in T1D; at diagnosis only about 1/3 or less of the presumed beta cell volume remains (6) . A so far neglected area of investigation has been the actual number of islets present in subjects with T1D; in non-diabetic subjects islet density averages about 25 islets/mm 2 during childhood and is less than 10 islets/mm 2 in adults (2) . Only few studies have indirectly reported data from which the number of islets per volume or area of pancreas can be extracted. Importantly, these studies align with the herein presented results, i.e. a reduction in the range of 30-70% in subjects affected by T1D when compared to non-diabetic controls (7-13).
Our observations of reduced number of islets/mm 2 in T1D should be viewed in relation to the apparent absence in the literature of reports on significant beta-cell destruction or apoptosis in subjects with T1D (14) . Almost all publications in humans affected by T1D show few T cells residing in the peri-islet area of only few islets but without aggressive T cell infiltration and ongoing beta cell destruction. Also, no correlation has been found between remaining beta cell mass and the frequency of insulitis (15) .
The islet size distribution as well as the mean islet size was similar in all three groups examined herein. These results indicate that the remaining islets in both subjects with recent onset as well as longstanding T1D contain a similar number of cells, but with a markedly changed phenotype of cells. In subjects with longstanding T1D, almost all remaining cells within the islets were alpha cells. Also, most islets in the DiViD subjects contained significantly larger proportion of alpha cells when compared with that in non-diabetic subjects. Already in 1978, Gepts et al reported on increased relative numbers of alpha-cells in both recent-onset and long standing T1D patients (8) . An important role for glucagon in T1D pathology has been suggested and exaggerated plasma glucagon responses to mixed-meal are observed in children and adolescents with T1D within the first 2 years of diagnosis (16) .
Focal lesions of acute pancreatitis with accumulation of leukocytes, often located around the ducts, are frequently observed in subjects with recent onset T1D (8) and most patients display extensive periductal fibrosis, the end stage of inflammation (17) . An injurious inflammatory adverse event occurring within the periductal area may have negative implications for islet neogenesis; dependent on stem cells residing within or adjacent to the ductal epithelium (3; 18). Failure to expand beta-cell mass during childhood would lead to prolonged periods of beta cell exhaustion and finally clinically overt T1D. Several studies in subjects with recent-onset T1D have shown an almost absent insulin-secretory response after intravenous injection of glucose. However, in response to oral glucose (triggering the incretin effect) or after an intravenous injection of arginine, these subjects release significant amounts of insulin (19; 20) . This "glucose-blindness" can conceivably be considered as the first sign of beta cell exhaustion.
The first report on dedifferentiation of beta cells in rats with chronic hyperglycemia was published already in 1999 (21) . The transcription factor FOXO1 has key role in the process: lineage-tracing experiments in mice with somatic deletion of FOXO1 in beta cells showed reduced numbers of beta cells caused by dedifferentiation to alpha cells, not beta cell death, in situations with beta cell stress (22) . These results were recently corroborated also in human type 2 diabetes (T2D)
were a large fraction of beta cells dedifferentiated to alpha or delta cell phenotypes (23) .
Notably, dissociation of human islets into single cells, and subsequent reaggregation into clusters, cause degranulation of beta cells that seems to trigger dedifferentiation of most beta cells into glucagon expressing cells (24) but with retained expression of the beta cell specific transcription factors PDX1 and NKX6.1.
Surprisingly, this process of beta cell loss has not so far been explored in T1D. Similar to the herein reported finding of PDX1 reactivity in the nuclei in a large proportion of the alpha cells, a recent publication on impaired alpha cell function in T1D showed that most alpha cells in donors with T1D do not express the alpha cell transcription factors MAFB and ARX, but low levels of NKX6.1 (25) . Obtained findings were interpreted as that only a partial change from an alpha toward a beta cell phenotype had occurred.
Hence, similar observations in T1D and T2D have been interpreted in different ways:
in T2D to support the hypothesis of beta cell dedifferentiation to alpha cells as a mechanism for beta cell loss, whereas in T1D to support the hypothesis of beta cell neogenesis from alpha cells.
Assessment of the total number of islets within the pancreas would have required access to the entire pancreas, however, only the tail of the pancreas was resected in the DiViD subjects. Islet density in non-diabetic subjects has been reported to be slightly increased (≈10%) in the tail when compared to the head and corpus and the results presented here may not be representative for the whole pancreas. The results should, however, be comparable between all groups as the tail was examined also in the organ donor pancreases.
Collectively, our findings suggest that acute massive beta-cell destruction in T1D is not occurring recently after clinical diagnosis. Neither has this been described in other published reports on subjects with recent onset T1D. We suggest that dedifferentiation of beta cells could explain a maintained islet size distribution and that loss of endocrine mass is mainly due to processes affecting entire islets.
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